Health-Related Quality of Life in Patients with Moderate to Advanced Dry Age-Related Macular Degeneration: Results from a Phase 1/2a Clinical Trial of Cnto 2476

Abstract

Objectives: To evaluate the impact of dry eye disease (DED) on health-related quality of life, work productivity, daily activities, and healthcare resource use. MethOds: Data were analyzed from participants (≥ 18 years) of the 2013 National Health and Wellness Survey. Participants were classified as: Diagnosed-DED, Symptomatic-Undiagnosed (undiagnosed but experienced DED symptoms), and Non-DED (no DED diagnosis/symptoms). Outcome measures included: the Short Form (SF)-36 health survey (mental component summary [MCS], physical component summary [PCS]; 0-100 scale, higher= better health status), Work Productivity and Activity Impairment (WPAI) questionnaire (absenteeism, presenteeism, impairment in daily activities in past 7 days), and healthcare resource use. Multivariate regression was used to estimate adjusted group effects relative to the Non-DED group for each outcome, controlling for age, sex, insurance type, socio-demographic and lifestyle factors, and comorbidities. Results: There were a total of 74,095 participants (mean age 48 years (SD 17), 52% women): 5,042 Diagnosed-DED, 1,785 Symptomatic-Undiagnosed, and 67,268 Non-DED. For each measure, Diagnosed-DED and Symptomatic-Undiagnosed participants had significantly worse outcomes than the Non-DED group (P< 0.001 for all comparisons). For the Diagnosed-DED, Symptomatic-Undiagnosed, and Non-DED groups, mean (SD) scores for the SF-36

Therapeutic effects of various therapeutic strategies on non-exudative age-related macular degeneration

“…In addition, intravitreal injection of autologous bone-marrow stem cells (ABMSCs) in DAMD treatment has been applied in a clinical non-randomized trial and showed a slight improvement effect for visual acuity; however, large scale RCTs are needed to confirm these results (NCT01518127). [37]…”